2 Under closer scrutiny
The mechanisms of hydroxychloroquine are related to potential cardiotoxic manifestations and demonstrate potential adverse effects when used for coronavirus disease 2019
In the prevention and treatment of Coronavirus disease 2019 (COVID-19) in the United States, 74% trust their health care providers
In this national, population-based study of hydroxychloroquine users, we found no evidence that pre-exposure use of hydroxychloroquine was associated with
CQ obtained from the bark of Cinchona trees has been widely used for a long time as an antimalarial agent []
Neither
Hydroxychloroquine and chloroquine (used with or without a macrolide) are widely advocated for treatment of COVID-19 based on in-vitro evidence of an antiviral effect against severe acute respiratory syndrome coronavirus 2
Hydroxychloroquine (HCQ) emerged early in the course of the coronavirus disease 2019 (COVID-19) pandemic as a possible drug with potential therapeutic and prophylactic benefits
Hydroxychloroquine and a related drug, chloroquine, are not recommended for use in treating COVID-19 (the illness caused by the new coronavirus)
Favorable inhibition of virus spread was observed when the cells were either treated with chloroquine prior to or after SARS CoV infection
Hydroxychloroquine was shown to have equivalent antimalarial activity and to be slightly less toxic in experimental animals []
The disease rapidly spread to at least 30 countries within months of its first appearance, and concerted worldwide efforts led to the identification of the etiological agent as SARS coronavirus
Additionally, many people with an actual medical need to take hydroxychloroquine – like those living with lupus and related autoimmune diseases – found themselves unable to obtain the drugs Abstract
1, 2 This pandemic’s effects on high-risk populations are still being studied
A good clinical outcome with virological cure was reported in 973 patients (91%) within 10 days out of 1,061 hydroxychloroquine-treated patients
(2020), hospitalized patients with respiratory illness from COVID-19 that were administered hydroxychloroquine compared with placebo, did not show significant improvement clinically after 14 days